Statements Of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Cash flows from operating activities
Net loss	$ (5,286,720)	$ (7,352,775)
Adjustments to reconcile net loss to cash used in operating activities:
Depreciation	367,611	320,301
Amortization of intangibles	199,320	299,833
Amortization of deferred finance costs	188,239	222,682
Share-based compensation	1,365,121	1,312,319
Gain on debt extinguishment	(5,632,171)
Noncash interest	485,857	449,814
Adjustment of warrants	2,009,150	(1,340,057)
Changes in operating assets and liabilities:
Accounts receivable	1,710,511	104,029
Inventories	(853,171)	1,521,995
Prepaid expenses and other current assets	(187,940)	86,944
Other assets	(7,548)	124,691
Accounts payable	782,875	(512,998)
Accrued liabilities	(1,567,226)	798,696
Deferred revenue	(181,468)	1,820,798
Other liabilities	44,806	(384,773)
Net cash used in operating activities	(6,562,754)	(2,528,501)
Cash flows from investing activities
Purchase of Fixed Asset	(410,184)	(153,151)
Net cash used in investing activities	(410,184)	(153,151)
Cash flows from financing activities
Payments of deferred financing costs	(100,000)
Proceeds from revolving line of credit	7,650,000
Payments of revolving line of credit	(7,650,000)
Proceeds from (payments of) Healthcare Royalty Partners debt	(13,020,780)	40,413
Proceeds from issuance of stock, net of issuance costs	23,001,528	964,520
Net cash provided by (used in) financing activities	9,880,748	1,004,933
Net increase (decrease) in cash and cash equivalents	2,907,810	(1,676,719)
Cash and cash equivalents at beginning of period	5,593,582	7,270,301
Cash and cash equivalents at end of period	8,501,392	5,593,582
Supplemental disclosures of cash flow information:
Interest paid	$ 2,253,554	$ 2,974,345